{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:12:39Z","timestamp":1792692759118,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T00:00:00Z","timestamp":1565222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CTRF- MR\/R001332\/1"],"award-info":[{"award-number":["CTRF- MR\/R001332\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.phrs.2019.104392","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T12:48:33Z","timestamp":1565268513000},"page":"104392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors"],"prefix":"10.1016","volume":"147","author":[{"given":"Katie","family":"Bechman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2019.104392_bib0005","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0010","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2019.104392_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.phrs.2019.104392_bib0020","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/emboj\/18.6.1549","article-title":"Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain","volume":"18","author":"Cacalano","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2019.104392_bib0025","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104392_bib0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104392_bib0035","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O\u2019Shea","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2019.104392_bib0040","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2019.104392_bib0045","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-013-0065-8","article-title":"Tofacitinib: a review of its use in adult patients with rheumatoid arthritis","volume":"73","author":"Scott","year":"2013","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.phrs.2019.104392_bib0050","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol. (Baltimore, Md: 1950)"},{"key":"10.1016\/j.phrs.2019.104392_bib0055","unstructured":"(EMA) EMA. Xeljanz: EPAR \u2013 Product Information. Xeljanz -EMEA\/H\/C\/004214 -IB\/0001 31\/03\/2017 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004214\/WC500224911.pdf."},{"key":"10.1016\/j.phrs.2019.104392_bib0060","unstructured":"(EMA) EMA. Olumiant: EPAR \u2013 Product Information (PDF). Olumiant -EMEA\/H\/C\/004085 -II\/0001 16\/03\/2017 http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/ 004085\/WC500223723.pdf."},{"issue":"6","key":"10.1016\/j.phrs.2019.104392_bib0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.phrs.2019.104392_bib0070","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104392_bib0075","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"Kremer","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"9865","key":"10.1016\/j.phrs.2019.104392_bib0080","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2019.104392_bib0085","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"van der Heijde","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.phrs.2019.104392_bib0090","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10093","key":"10.1016\/j.phrs.2019.104392_bib0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet"},{"issue":"suppl. 10","key":"10.1016\/j.phrs.2019.104392_bib0100","article-title":"Real world results from a post-approval safety surveillance of tofacitinib (Xeljanz): over 3 year results from an ongoing US-Based rheumatoid arthritis registry [abstract]","volume":"68","author":"Kavanaugh","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104392_bib0105","article-title":"THU0132 comparative effectiveness of TNFI and tofacitinib monotherapy in clinical practice: results from corrona registry","volume":"75","author":"Reed","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.104392_bib0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0115","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2169\/internalmedicine.9341-17","article-title":"Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naive and experienced patients","volume":"57","author":"Mori","year":"2018","journal-title":"Intern. Med. (Tokyo, Japan)"},{"issue":"suppl 10","key":"10.1016\/j.phrs.2019.104392_bib0120","first-page":"69","article-title":"Effectiveness, Tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen Cohort [abstract]","volume":"2017","author":"Mueller","year":"2017","journal-title":"Rthritis Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104392_bib0125","article-title":"THU0174 Drug retention of tofacitinib versus biologic antirheumatic agents in rheumatoid arthritis: observational data from the swiss scqm registry","volume":"76","author":"Ciurea","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"16","key":"10.1016\/j.phrs.2019.104392_bib0130","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.phrs.2019.104392_bib0135","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104392_bib0140","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1136\/annrheumdis-2018-eular.3115","article-title":"SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study","volume":"77","author":"Nash","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0145","first-page":"21","article-title":"Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders","volume":"9","author":"D\u2019Angelo","year":"2017","journal-title":"Open Access Rheumatol. Res. Rev."},{"issue":"3","key":"10.1016\/j.phrs.2019.104392_bib0150","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"9993","key":"10.1016\/j.phrs.2019.104392_bib0155","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0160","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.phrs.2019.104392_bib0165","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2019.104392_bib0170","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"issue":"13","key":"10.1016\/j.phrs.2019.104392_bib0175","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1080\/14656566.2017.1359256","article-title":"Efficacy of baricitinib in the treatment of rheumatoid arthritis","volume":"18","author":"Richez","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2019.104392_bib0180","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and No or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"issue":"1","key":"10.1016\/j.phrs.2019.104392_bib0185","first-page":"88","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study","volume":"76","author":"Dougados","year":"2017","journal-title":"Clin. Epidemiol. Res."},{"key":"10.1016\/j.phrs.2019.104392_bib0190","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-211259","article-title":"Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study","author":"Keystone","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0195","article-title":"Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0200","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.2000","article-title":"Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study","author":"Takeuchi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2019.104392_bib0205","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104392_bib0210","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.104392_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.phrs.2019.104392_bib0220","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","article-title":"Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs","volume":"75","author":"Charles-Schoeman","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104392_bib0225","article-title":"SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates","volume":"77","author":"Schwartzman","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.104392_bib0230","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.phrs.2019.104392_bib0235","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/acr2.1010","article-title":"Persistence of tofacitinib in the treatment of rheumatoid arthritis in open\u2010label, long\u2010term extension studies up to 9.5 years","volume":"1","author":"Pope","year":"2019","journal-title":"ACR Open Rheumatol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0240","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.phrs.2019.104392_bib0245","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"issue":"3","key":"10.1016\/j.phrs.2019.104392_bib0250","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.chembiol.2011.01.012","article-title":"Jak1 has a dominant role over Jak3 in signal transduction through \u03b3c-containing cytokine receptors","volume":"18","author":"Haan","year":"2011","journal-title":"Chem. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104392_bib0255","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/bcp.13329","article-title":"Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib","volume":"83","author":"Mohamed","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104392_bib0260","article-title":"Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials","author":"Kl\u00fcnder","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.phrs.2019.104392_bib0265","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"issue":"10139","key":"10.1016\/j.phrs.2019.104392_bib0270","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"10139","key":"10.1016\/j.phrs.2019.104392_bib0275","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"suppl. 10","key":"10.1016\/j.phrs.2019.104392_bib0280","article-title":"A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-na\u00efve patients with active rheumatoid arthritis [abstract]","volume":"70","author":"van Vollenhoven","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104392_bib0285","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/annrheumdis-2018-eular.4237","article-title":"OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2019.104392_bib0290","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/13543784.2017.1372422","article-title":"Filgotinib for the treatment of rheumatoid arthritis","volume":"26","author":"Taylor","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"8","key":"10.1016\/j.phrs.2019.104392_bib0295","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.phrs.2019.104392_bib0300","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0305","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.3862","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","author":"Kavanaugh","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"10162","key":"10.1016\/j.phrs.2019.104392_bib0310","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"issue":"10162","key":"10.1016\/j.phrs.2019.104392_bib0315","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2019.104392_bib0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"13","key":"10.1016\/j.phrs.2019.104392_bib0325","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.phrs.2019.104392_bib0330","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104392_bib0335","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study","author":"Takeuchi","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0340","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104392_bib0345","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-Severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0350","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop -2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2019.104392_bib0355","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.phrs.2019.104392_bib0360","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0365","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","author":"Smolen","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104392_bib0370","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2019.104392_bib0375","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis & Rheumatol. (Hoboken, NJ)"},{"issue":"10","key":"10.1016\/j.phrs.2019.104392_bib0380","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104392_bib0385","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/annrheumdis-2016-eular.1612","article-title":"THU0166 safety profile of baricitinib in patients with active RA: an integrated analysis","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0390","doi-asserted-by":"crossref","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","author":"Dunn","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0395","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0400","series-title":"ACR\/ARHP Annual Meeting. 2017 October 19, 2017","article-title":"Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs","author":"Mease","year":"2017"},{"issue":"suppl 10","key":"10.1016\/j.phrs.2019.104392_bib0405","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis [abstract]","volume":"69","author":"Weinblatt","year":"2017","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"key":"10.1016\/j.phrs.2019.104392_bib0410","article-title":"Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study","author":"Ogdie","year":"2017","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.phrs.2019.104392_bib0415","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/art.38974","article-title":"Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib","volume":"67","author":"Charles-Schoeman","year":"2015","journal-title":"Arthritis & Rheumatol. (Hoboken, NJ)"},{"issue":"18","key":"10.1016\/j.phrs.2019.104392_bib0420","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/bph.13932","article-title":"Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis","volume":"174","author":"Perez-Baos","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104392_bib0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/annrheumdis-2012-202442","article-title":"Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study","volume":"73","author":"McInnes","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2019.104392_bib0430","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.40036","article-title":"Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis","volume":"69","author":"Kremer","year":"2017","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"issue":"7","key":"10.1016\/j.phrs.2019.104392_bib0435","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104392_bib0440","article-title":"Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients","author":"Xie","year":"2018","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"10.1016\/j.phrs.2019.104392_bib0445","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-207838","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","author":"Richter","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.phrs.2019.104392_bib0450","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"key":"10.1016\/j.phrs.2019.104392_bib0455","series-title":"Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 5.5 Years: An Updated Integrated Safety Analysis","author":"Genovese","year":"2017"},{"issue":"3","key":"10.1016\/j.phrs.2019.104392_bib0460","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Richter","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2019.104392_bib0465","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf."}],"updated-by":[{"DOI":"10.1016\/j.phrs.2020.104634","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000}}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:31:43Z","timestamp":1778581903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819310229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":93,"alternative-id":["S1043661819310229"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104392","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104392"}}